72011524RFA00003: Tuberculosis (TB) Bilateral Activity in the Kyrgyz Republic
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Kazakhstan USAID-Almaty notices from 2024.
Kazakhstan USAID-Almaty offered grants of up to $21.5 million (at least $1) to any type of organization. It expected to make one award. Applications closed on April 22, 2024.
From the official notice on Grants.gov, last changed March 7, 2024. Checked November 7, 2026.
- Award ceiling$21.5 million
- Award floor$1
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 7, 2024 |
|---|---|
| Deadline | April 22, 2024 |
| Archived by Grants.gov | May 22, 2024 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Past USAID Foreign Assistance for Programs Overseas awards averaged $8.7 million; this notice allows up to $21.5 million per award.
- Most of the program's money (54% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The goal of the activity is to reduce the burden of tuberculosis (TB) in the Kyrgyz Republic by reducing the TB incidence and mortality. The New TB Activity will build on the existing strengths of the National TB Program to accomplish lasting change through proven approaches such as interrupting TB transmission in communities, scaling up of prevention interventions, increasing TB case finding and ensuring all people with TB successfully complete treatment to stop spreading the disease.
Who has won USAID Foreign Assistance for Programs Overseas grants before
From fiscal 2021 to 2025, USAID Foreign Assistance for Programs Overseas (98.001) awarded $37 billion across 4,233 grant awards, an average of $8.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Miscellaneous Foreign Awardees | District of Columbia | 489 | $6.9 billion |
| Family Health International | North Carolina | 91 | $2.1 billion |
| Catholic Relief Services - United States Conference of Catholic Bishops | Maryland | 128 | $1.2 billion |
| Save the Children Federation, Inc. | Connecticut | 100 | $814 million |
| Research Triangle Institute | North Carolina | 33 | $756 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is 72011524RFA00003 still open?
No. It closed on April 22, 2024.
Who can apply for Tuberculosis (TB) Bilateral Activity in the Kyrgyz Republic?
Kazakhstan USAID-Almaty accepted applications from any type of organization.
What is the deadline for Tuberculosis (TB) Bilateral Activity in the Kyrgyz Republic?
Closed April 22, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $21.5 million each.
Who has won USAID Foreign Assistance for Programs Overseas grants before?
The largest recipients over five fiscal years were Miscellaneous Foreign Awardees, Family Health International, Catholic Relief Services - United States Conference of Catholic Bishops. The program made 4,233 awards worth $37 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)